Backs FY23 adjusted EBITDA view (50M)-(30M). “We made significant strides in 2023 and expect to achieve meaningful profitability in 2024, an important milestone for the company. We have a robust pipeline of strategic partnerships that will drive growth and further validate the P3 business model. And our business continues to gain momentum across all key performance metrics including managing medical cost trend,” said Dr. Sherif Abdou, co-founder and CEO of P3.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
